STUDY SCHEMA

Eligibility
- Metastatic or locally recurrent gastro-oesophageal cancer
- Adenocarcinoma or undifferentiated carcinoma
- Failed or intolerant to minimum of 2/maximum of 3 lines of prior anti-cancer therapy

Stratification
- Location of tumour (GOJ vs gastric)
- Geographic region (Asia vs Rest of World)
- Prior VEGF inhibitors (Y/N)

![Diagram]

Regorafenib
160mg (4 x 40mg tablets) orally, once daily on days 1-21 of each 28 day cycle + Best Supportive Care until progression

Placebo
160mg (4 x 40mg tablets) orally, once daily on days 1-21 of each 28 day cycle + Best Supportive Care until progression

Endpoints
- Overall survival (Primary)
- Progression free survival (PFS)
- Objective tumour response rate (RR)
- Quality of life (QoL)
- Safety
- Biomarkers
- Pharmacokinetics (PK)